ReviewJACC. Basic to translational science2026
Emerging Role of Sodium-Glucose Cotransporter-2 Inhibitors in Aortic Stenosis.
Review in JACC. Basic to translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a key drug class in the management of heart failure, expanding far beyond their original use in type 2 diabetes mellitus. Aortic stenosis (AS), the most common valvular heart disease in the aging population, is characterized by progressive valve calcification and chronic left ventricular pressure overload. No disease-modifying pharmacologic treatment has yet been found to slow AS progression or to prevent myocardial remodeling in AS. The authors review the mechanistic rationale for SGLT2 inhibition in the pressure-overloaded heart and summarize the emerging evidence in AS. The authors propose that SGLT2 inhibition may represent a promising strategy targeting both myocardial remodeling and valvular disease biology in AS, warranting further investigation in dedicated trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.